成纤维细胞生长因子15/19(FGF15/19)可预防饮食诱导的肝脂肪变性:开发基于FGF19的嵌合分子以促进脂肪肝再生
研究探讨FGF15/19在高脂饮食及饱和脂肪酸调节中的作用,并构建FGF19与载脂蛋白A-I的融合分子Fibapo。Fgf15-/-小鼠高脂饮食后肝脂肪变性和内质网应激加重,棕榈酸可诱导小鼠回肠及人肝细胞FGF15/19表达,FGF19可减轻棕榈酸所致内质网应激和细胞毒性。Fibapo降低肝胆汁酸和脂质蓄积、抑制内质网应激并延长半衰期,在肥胖db/db小鼠部分肝切除后提高生存率并改善再生。
要点
- FGF15/19是膳食脂肪肝脏代谢适应的必需因子,为Pparγ2表达的生理调节因子。
- 棕榈酸可诱导小鼠回肠和人肝细胞FGF15/19表达,FGF19保护棕榈酸所致内质网应激和细胞毒性。
- Fibapo围手术期给药可改善肥胖db/db小鼠脂肪肝再生并提高部分肝切除后生存率。
核心结论
- FGF15/19是膳食脂肪肝脏代谢适应的必需因子,为Pparγ2表达的生理调节因子;Fibapo围手术期给药可改善脂肪肝再生。
研究设计与样本
- 研究采用Fgf15-/-小鼠高脂饮食模型、小鼠及人肝细胞系体外实验,并比较Fibapo与FGF19的体内半衰期和生物活性。
- 在肥胖db/db小鼠部分肝切除模型中评估Fibapo的保肝和促再生作用。
主要发现
- 高脂饮食喂养的Fgf15-/-小鼠肝脂肪变性和内质网应激加重。
- Fgf15-/-小鼠肝脏Pparγ2表达升高,FGF19治疗可逆转该升高。
- 棕榈酸诱导小鼠回肠和人肝细胞FGF15/19表达,FGF19保护棕榈酸介导的内质网应激和细胞毒性。
- Fibapo降低肝脏胆汁酸和脂质蓄积、抑制内质网应激并显示延长的半衰期。
- Fibapo提高db/db小鼠部分肝切除后生存率并改善再生。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fibroblast growth factor 15/19 (FGF15/19), an enterokine that regulates synthesis of hepatic bile acids (BA), has been proposed to influence fat metabolism. Without FGF15/19, mouse liver regeneration after partial hepatectomy (PH) is severely impaired. We studied the role of FGF15/19 in response to a high fat diet (HFD) and its regulation by saturated fatty acids. We developed a fusion molecule encompassing FGF19 and apolipoprotein A-I, termed Fibapo, and evaluated its pharmacological properties in fatty liver regeneration. DESIGN: Fgf15-/- mice were fed a HFD. Liver fat and the expression of fat metabolism and endoplasmic reticulum (ER) stress-related genes were measured. Influence of palmitic acid (PA) on FGF15/19 expression was determined in mice and in human liver cell lines. In vivo half-life and biological activity of Fibapo and FGF19 were compared. Hepatoprotective and proregenerative activities of Fibapo were evaluated in obese db/db mice undergoing PH. RESULTS: Hepatosteatosis and ER stress were exacerbated in HFD-fed Fgf15-/- mice. Hepatic expression of Pparγ2 was elevated in Fgf15-/- mice, being reversed by FGF19 treatment. PA induced FGF15/19 expression in mouse ileum and human liver cells, and FGF19 protected from PA-mediated ER stress and cytotoxicity. Fibapo reduced liver BA and lipid accumulation, inhibited ER stress and showed enhanced half-life. Fibapo provided increased db/db mice survival and improved regeneration upon PH. CONCLUSIONS: FGF15/19 is essential for hepatic metabolic adaptation to dietary fat being a physiological regulator of Pparγ2 expression. Perioperative administration of Fibapo improves fatty liver regeneration.
引用
- Alvarez-Sola G, Uriarte I, Latasa MU, et al. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut. 2017. PMID: 28119353. doi:10.1136/gutjnl-2016-312975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。